# Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

> **NCT00238615** · PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 13 (actual)

## Conditions studied

- Lung Cancer
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **PROCEDURE:** Radiation therapy
- **PROCEDURE:** Surgical resection

## Key facts

- **NCT ID:** NCT00238615
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** 2009-09
- **Final completion:** 2014-11
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2015-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00238615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00238615, "Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00238615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*